Top 10 Prescription Diet Pills That Work Fast
What are the top 10 prescription diet pills that work fast? As obesity has become a real issue of late (more than 2 in 3 adults are considered to be overweight or obese), sometimes...
Posts Tagged ‘Belviq’
Pharma News: Vivus, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA)’s Settled Stock & Amgen, Inc. (AMGN)’s Clinical Trial
Investors in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) saw new options become available this week, for the April 2014 expiration. ...VIVUS, Inc.
Pharma News: VIVUS, Inc. (VVUS) Qsymia Patents, Arena Pharmaceuticals, Inc. (ARNA) Earnings, Amgen, Inc. (AMGN) Ending an Agreement
Earlier today RFD IP Business Services ("RFD") released a new report analyzing the likely inequitable conduct challenges to VIVUS, Inc.
Pharma News: Vivus, Inc. (VVUS)’s New CEO, Arena Pharmaceuticals, Inc. (ARNA) & Amgen, Inc. (AMGN)’s Positive Earnings
VIVUS, Inc. (NASDAQ:VVUS), which sells the obesity drug Qsymia, has appointed Anthony Zook to serve as its CEO.
Trending News: Exxon Mobil Corporation (XOM), Arena Pharmaceuticals, Inc. (ARNA), QUALCOMM, Inc. (QCOM)
Editor's Note: Related tickers: Exxon Mobil Corporation (NYSE:XOM), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), 3M Co (NYSE:MMM), Akamai Technologies, Inc.
Arena Pharmaceuticals Inc. (ARNA): What to Expect from Earnings
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) gets its turn in the earnings parade Thursday when it releases its quarterly report after the closing bell.
Risks in the Pharma Sector: Amarin, VIVUS and Arena Pharmaceuticals
It has been interesting to note with great fascination the crazy unpredictability in the pharmaceutical sector of the market, most notably Amarin (NASDAQ:AMRN), Arena Pharmaceuticals...
FDA Approval: End of Arena, VIVUS Running Out of Adrenaline?
The celebrations must be over. That was fast. Arena Pharmaceuticals (NASDAQ:ARNA) and VIVUS Inc.
Arena Pharmaceuticals vs. Vivus: Which Is a Better Weight Loss Drug for Investors?
Arena Pharmaceuticals (NASDAQ:ARNA) and Vivus (NASDAQ:VVUS) are battling in the minds of investors as each promises a drug with the potential to cause weight loss- a sure moneymaker...
Can Vivus Inc. Ride Qsymia to Market Success and Big Returns?
Since last week's news that Vivus, Inc. (NASDAQ:VVUS) received FDA approval for its obesity drug Qsymia, the raging battle between Vivus and Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc.: With Belviq Approval, Now What?
In the pharmaceutical sector of the market, many eyes have been on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and its fierce competitor, Vivus, Inc.
